

Improvement of the metabolic syndrome profile by soluble fibre – guar gum – in patients with type 2 diabetes: a randomised clinical trial

Valesca Dall'Alba^{1,2}, Flávia Moraes Silva¹, Juliana Peçanha Antonio¹, Thais Steemburgo^{1,2}, Caroline Persh Royer¹, Jussara Carnevale Almeida^{1,2}, Jorge Luiz Gross¹ and Mirela Jobim Azevedo^{1*}

¹Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2350 – Prédio 12, 4º andar, 90035-003 Porto Alegre, RS, Brazil

²Nutrition Course, Departamento de Medicina Interna, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

(Submitted 21 August 2012 – Final revision received 5 March 2013 – Accepted 5 March 2013 – First published online 3 April 2013)

Abstract

A diet rich in fibre seems to protect against the metabolic syndrome (MetS), but there is scarce information about the role of fibre intake in patients with the MetS and diabetes. The aim of the present study was to evaluate the effects of soluble fibre from partially hydrolysed guar gum (PHGG) on the MetS and cardiovascular risk factors in patients with type 2 diabetes. In the present randomised controlled clinical trial, forty-four patients with type 2 diabetes (males 38·6%, age 62 (SD 9) years, diabetes duration 14·2 (SD 9·6) years) and the MetS underwent clinical, laboratory and dietary evaluations at baseline, 4 and 6 weeks. All patients followed their usual diet and the intervention group (*n* 23) received an additional 10 g/d of PHGG. In the intervention group, waist circumference (WC), glycated Hb (HbA1c), 24 h urinary albumin excretion (UAE) and serum *trans*-fatty acids (FA) were reduced in comparison with baseline after 4 and 6 weeks: WC 103·5 (SD 9·5) to 102·1 (SD 10) to 102·3 (SD 9·7) cm; HbA1c 6·88 (SD 0·99) to 6·64 (SD 0·94) to 6·57 (SD 0·84)%; 24 h UAE 6·8 (interquartile range 3·0–17·5) to 4·5 (interquartile range 3·0–10·5) to 6·2 (interquartile range 3·0–9·5) mg; *trans*-FA 71 (interquartile range 46–137) to 67 (interquartile range 48–98) to 57 (interquartile range 30–110) mg/l (*P*<0·05 for all). The only change in the control group was weight reduction: 77·0 (SD 13·5) to 76·2 (SD 13·3) to 76·1 (SD 13·4) kg (*P*=0·005). Other MetS components (blood pressure, TAG, HDL-cholesterol, fasting plasma glucose), total and LDL-cholesterol, C-reactive protein and endothelin-1 did not change in either group. In patients with type 2 diabetes and the MetS, the addition of PHGG to the usual diet improved cardiovascular and metabolic profiles by reducing WC, HbA1c, UAE and *trans*-FA.

Key words: Dietary fibre: Diabetes mellitus: Metabolic syndrome: Waist circumference

The metabolic syndrome (MetS), which refers to a cluster of risk factors including central obesity, low serum HDL-cholesterol and increased serum TAG, blood pressure and blood glucose⁽¹⁾, doubles the risk of cardiovascular outcomes and increases the risk for all-cause mortality⁽²⁾. The MetS occurs in 85% of patients with type 2 diabetes⁽³⁾, and the greater the number of MetS components, the greater the frequency of coronary artery disease and microvascular chronic complications⁽⁴⁾.

Dietary intervention plays an important role in the management of MetS components⁽⁵⁾. Diets with high fibre content improve most MetS components in non-diabetic individuals^(6,7). However, there is scarce information about the effects of fibre consumption in patients with diabetes and the MetS. In patients with type 2 diabetes, we have recently demonstrated

that a low total fibre content, associated with consumption of high dietary glycaemic index foods, was positively associated with the presence of the MetS⁽⁸⁾. Additionally, the intake of soluble fibres, especially from whole-grain foods and fruits, was negatively associated with the presence of the MetS in patients with type 2 diabetes⁽⁹⁾.

The beneficial effects of fibre on glucose and lipid abnormalities have mostly been attributed to soluble rather than insoluble fibre⁽⁵⁾. Partially hydrolysed guar gum (PHGG) is a natural water-soluble dietary fibre obtained by the controlled partial enzymatic hydrolysis of guar gum (GG) that is tasteless and can be easily added to the diet^(10,11). Some studies have suggested that the intake of GG reduces plasma glucose levels^(12–15) as well as improves the lipid profile^(12,14–18) in patients with type 2 diabetes. However, other

Abbreviations: FA, fatty acid; GG, guar gum; HbA1c, glycated Hb; MetS, metabolic syndrome; PHGG, partially hydrolysed guar gum; UAE, urinary albumin excretion; WC, waist circumference.

* **Corresponding author:** M. J. Azevedo, fax +55 51 33598777, email mirelajobimazevedo@gmail.com

studies have not confirmed these beneficial effects of GG both in glucose^(16–18) and lipid levels⁽¹³⁾. The possible effects of GG on MetS components in patients with type 2 diabetes and the MetS are still unknown. Therefore, the aim of the present study was to evaluate the effects of PHGG on the MetS in patients with type 2 diabetes.

Subjects and methods

The present randomised, open-label, parallel, controlled clinical trial study was conducted in patients with type 2 diabetes and the MetS. The primary outcomes were MetS components (central obesity, serum HDL-cholesterol and TAG, blood pressure values and blood glucose)⁽¹⁹⁾. The values of glycated Hb (HbA1c), 24 h urinary albumin excretion (UAE), serum fatty acids (FA), high-sensitivity C-reactive protein and plasma endothelin-1 were secondary outcomes. The present study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human patients were approved by the Research Ethics Committee of the Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil. Written informed consent was obtained from all patients. The present trial was registered at clinicaltrials.gov as NCT 01071785.

Patients and study protocol

Patients with type 2 diabetes, who consecutively attended the Endocrine Division's outpatient clinic at Hospital de Clínicas de Porto Alegre, Brazil, were selected based on the following criteria: presence of the MetS; HbA1c <9%; serum creatinine <176 µmol/l; UAE <200 mg/24 h; absence of malabsorption, urinary tract infection or other renal diseases.

Type 2 diabetic patients were defined based on diabetes onset at age ≥30 years, the absence of previous episodes of ketoacidosis or documented ketonuria and the start of treatment with insulin not before 5 years following diagnosis. Diagnosis of the MetS was based on the International Diabetes Federation criteria: central obesity (waist circumference (WC) ≥94 cm for men and ≥80 cm for women) and one of the following, considering that all patients had diabetes: TAG ≥1.695 mmol/l; HDL-cholesterol <1.036 mmol/l for men and <1.295 mmol/l for women; blood pressure ≥130/85 mmHg (or use of anti-hypertensive drugs); raised blood glucose or diabetes⁽¹⁹⁾.

A total of sixty-three eligible patients with type 2 diabetes, all of them with the MetS, entered a run-in period of 2 weeks (19.5 (SD 8)). Changes in medication were prescribed, if necessary, in order to stabilise blood pressure and blood glucose (anti-diabetic agents were standardised to metformin and/or neutral protamine Hagedorn insulin). Hypolipidaemic agents were temporarily discontinued 6 weeks before the beginning of the study. Patients were instructed to maintain their usual physical activity and diet. Soyabean oil and white bread were supplied for all patients in order to avoid differences in carbohydrate and fat contents between the intervention and control groups. White bread and soyabean oil were chosen because these foods are the most frequently

consumed by our type 2 diabetic patients according to our dietary record database⁽⁸⁾.

Patients were randomly assigned to the intervention group (PHGG, 5 g twice per d) or the control group. A sequential list established before the beginning of the protocol was used for randomisation. Clinical, laboratory and nutritional evaluations were performed at baseline, 4 and 6 weeks.

Intervention group: partially hydrolysed guar gum

PHGG soluble fibre is produced from GG by an enzymatic process and has the same chemical structure as native GG, with one-tenth of the length⁽¹⁰⁾. The intervention group (GG group) received a daily dietary supplementation of 10 g PHGG (Benefiber®; Novartis Brasil), taking one 5 g sachet at lunch and another at dinner. PHGG sachets were supplied and compliance was assessed at every visit by counting the number of return sachets. Non-compliance was defined as missing more than 10% of the total supplied PHGG sachets. Also, patients from the GG and control groups were asked to describe any unusual symptoms or signs in order to evaluate the possible side effects related to PHGG.

Clinical evaluation

Blood pressure was measured twice, after a 10 min rest, using a standard digital sphygmomanometer (Omron HEM-705CP; Omron Healthcare, Inc.). Hypertension was defined as blood pressure ≥140/90 mmHg, measured on two occasions, or the use of antihypertensive drugs⁽²⁰⁾. Patients were classified as normoalbuminuric (UAE <30 mg/24 h) or microalbuminuric (UAE 30–299 mg/24 h). Microalbuminuria was always confirmed by a second urinary measurement⁽²¹⁾. Fundus examination was performed and diabetic retinopathy was graded as present or absent.

Physical activity was graded in levels according to activities during a typical day based on a standardised questionnaire⁽²²⁾ adapted to local habits. Overall, four levels, from a sedentary lifestyle to high physical activity, were defined. Positive alcohol intake was considered in patients who mentioned the current intake of any amount of alcoholic beverage. Ethnicity was self-identified as white or non-white.

Nutritional assessment

The body weight and height of patients were obtained with measurements recorded to the nearest 100 g for weight and to the nearest 0.1 cm for height. BMI was calculated. WC was measured once to the nearest 1 cm midway between the lowest rib margin and the iliac crest, near the umbilicus, with a flexible, non-stretch fibreglass tape.

The patients' diet was assessed by 3 d weighed dietary records (two non-consecutive weekdays and one weekend day)⁽²³⁾. Patients were issued commercial scales and measuring cups. Records were analysed using Nutribase 2007 software (Clinical Nutrition Manager v.7.14; Cybersoft)⁽²⁴⁾. The total fibre content was estimated according to the *CRC Handbook of Dietary Fiber in Human Nutrition*⁽²⁵⁾. Data on

trans-FA were analysed as described previously^(9,26). Data intake from nutrients was expressed in crude amounts adjusted to total energy, unless otherwise stated. Compliance was confirmed by the measurement of a 24 h urinary N output and by the completeness of urine collection as evaluated by 24 h urinary creatinine.

Laboratory measurements

Blood samples were obtained after a 12 h fast. HbA1c was measured by an ion-exchange HPLC (Merck-Hitachi L-9100 glycosylated haemoglobin analyser, reference range 4.7–6.0%; Merck Diagnostica). UAE was measured by immunoturbidimetry (Microalb). Glomerular filtration rate was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation⁽²⁷⁾.

For serum FA analyses, blood samples were separated after centrifugation at 1500 *g* for 15 min and stored at -80°C for later laboratory measurements. FA were determined in TAG fractions by GC (Hewlett-Packard 6890; Agilent Technologies), as described previously⁽²⁸⁾. Methyl heneicosanoate (21:0) was used as an internal standard and the identity of each FA peak was ascertained by comparing the peak retention time with a previously characterised mixture of thirty-seven FA (Sigma-Aldrich). In our laboratory, the CV of each individual FA in this mixture ranged from 0.03 to 3.5%.

Statistical analyses

Sample size was calculated based on a putative decrease in at least two MetS components except diabetes. It was estimated that twenty-one participants would be required in each group to achieve a power of 80% and α of 0.05, taking into account a loss of 20%.

Student's *t* test, the Mann–Whitney *U* test and the χ^2 test were used as appropriate. Changes in outcomes were analysed by the general linear model for repeated measures, with measurements at different times considered as a within-subject factor, followed by a *post hoc* test (least significant difference) and adjusted for possible confounding factors (covariates). For each outcome analysis, covariates were chosen if they had a known biological influence on the evaluated outcome or had significantly changed during the study. Normally distributed dietary data were adjusted for energy intake through the residual method⁽²⁹⁾. Non-normally distributed variables were log-transformed before analyses. Results are expressed as means (standard deviations), medians (interquartile ranges) or number of patients with the characteristic (percentages). $P < 0.05$ was considered as statistically significant. SPSS 16.0 software (SPSS) was used for statistical analyses.

Results

Of the sixty-three eligible patients, seventeen were discharged during the run-in period: three were unable to maintain HbA1c $< 9\%$; seven were unwilling to attend the protocol visits and declined to participate; another seven due to other

reasons (three patients had poor compliance with the food-weighing technique, two underwent coronary angiographies, one developed macroalbuminuria and the last one developed recurrent urinary tract infection). Therefore, forty-six patients were randomised. After randomisation, two patients from the control group were discharged: one was inadvertently enrolled in another research protocol and the other developed persistent macroalbuminuria. Therefore, forty-four patients completed the protocol and only their data were included in the analyses. Fig. 1 shows the flow diagram of patient recruitment and randomisation.

Baseline patient characteristics

Baseline clinical and laboratory characteristics of patients with type 2 diabetes and the MetS are shown in Table 1. There were no differences between the GG and control groups regarding demographic features, anthropometric measurements, lifestyle characteristics, blood pressure values, frequency of chronic diabetic complications, laboratory test results and the proportion of the use of medications.

Dietary evaluation at baseline and during the study

Table 2 describes the dietary data. At baseline, no differences were observed in total daily energy and the intakes of protein, carbohydrates, fibres, total fat, MUFA, PUFA, SFA, *trans*-FA and cholesterol between the GG and control groups ($P > 0.05$ for all).

During the study, energy, carbohydrates, total fat, MUFA, PUFA, SFA and cholesterol intakes were reduced in the GG and control groups ($P > 0.05$ for all). Protein intake and *trans*-FA were reduced in the control group only.

Information about the total and soluble fibre intakes during the study was expressed as fibre intake with PHGG (including fibre from foods and PHGG) and fibre intake without PHGG (fibre from foods only). In the GG group, there was, as expected, an increase in total and soluble fibre intake when PHGG was taken into account. On the other hand, considering just fibre from foods, total fibre intake was reduced during the study in the control and GG groups. Insoluble fibre intake diminished in the two groups.

Metabolic syndrome and other cardiovascular risk factors during the study

WC was reduced from baseline to the 4th and 6th weeks only in the GG group, adjusted for changes in weight. No changes were observed in TAG, HDL-cholesterol, blood pressure values, fasting plasma glucose and frequency of the MetS during the study in both groups (Table 3).

Changes in other factors associated with cardiovascular risk in patients with diabetes are described in Table 4. The HbA1c values were reduced in the GG group, adjusted for changes in weight and baseline HbA1c values. Also, UAE was reduced in the GG group, taking into account concomitant changes in weight, blood pressure, protein intake and HbA1c. Body weight diminished only in the control group. No changes




Fig. 1. Flow diagram of recruitment and randomisation of patients with type 2 diabetes and the metabolic syndrome. HbA1c, glycated Hb; PHGG, partially hydrolysed guar gum.

were observed in total and LDL-cholesterol, serum creatinine, glomerular filtration rate, high-sensitivity C-reactive protein and plasma endothelin-1 in both groups.

Regarding FA evaluation, no changes occurred in total serum, SFA, MUFA and PUFA ($P > 0.05$ for all; data not shown) in the GG and control groups. However, a reduction in serum *trans*-FA was observed in the GG group: baseline 71 (interquartile range 46–137) mg/l; 4th week 67 (interquartile range 48–98) mg/l; 6th week 57 (interquartile range 30–110) mg/l ($P = 0.011$; least significant difference *post hoc* test: $P = 0.07$). This analysis was adjusted to changes in weight and intakes of total fat, *trans*-FA and energy.

Concerning PHGG compliance, only two patients missed PHGG sachets during the study (four sachets each one). PHGG was well tolerated without any serious adverse effect. Of the patients, four reported decreased appetite, fourteen had an increased number of bowel movements and three had diarrhoea in the first 2 d of use. The control group did not report any gastrointestinal symptom.

Discussion

The present randomised clinical trial demonstrated that in patients with type 2 diabetes and the MetS, a 6-week dietary supplementation with PHGG, a soluble fibre, had beneficial effects on the MetS profile and other factors associated with cardiovascular risk. The intake of PHGG reduced WC, HbA1c, albuminuria and serum *trans*-FA. These results were observed as early as 4 weeks after the start of this type of fibre supplementation, most lasting until the end of the study. In addition, the present study suggests a possible novel benefit of this soluble fibre in reducing *trans*-FA and albuminuria.

Fibre consumption seems to be protective against the presence of the MetS in non-diabetic subjects. Randomised clinical trials have demonstrated that diets with a high fibre content, such as the Mediterranean-style⁽⁶⁾ or Dietary Approaches to Stop Hypertension diets⁽⁷⁾ can reduce MetS prevalence. However, an independent fibre effect cannot be established based on these trials, since fibre content was not their primary focus.

Table 1. Baseline clinical and laboratory characteristics of patients with type 2 diabetes and the metabolic syndrome (Mean values and standard deviations; medians and interquartile ranges; number of patients and percentages with the analysed features)

	GG group (n 23)		Control group (n 21)		P
	Mean	SD	Mean	SD	
Males					0.944*
n	14		13		
%	60.9		61.9		
White ethnicity					0.341*
n	19		16		
%	82.6		76.2		
Age (years)	60.5	9.1	63.6	9.6	0.273†
Duration of diabetes (years)	11.8	8.1	16.9	10.6	0.084†
Weight (kg)	79.6	14.8	77.0	13.5	0.545†
BMI (kg/m ²)	30.2	3.6	29.3	3.6	0.426†
Waist circumference (cm)					
Male					0.500‡
Median	109		108		
Interquartile range	104–116		104–110		
Female					0.846‡
Median	100		100		
Interquartile range	91–106		92–106		
Current smoking					0.518*
n	1		3		
%	4.3		14.3		
Current alcohol intake					0.192*
n	4		7		
%	17.4		33.3		
Frequency of exercise: level 1					0.741*
n	11		9		
%	47.8		42.9		
Hypertension					0.605*
n	21		20		
%	91.3		95.2		
Systolic blood pressure (mmHg)	128.4	16.2	130.1	11.6	0.689†
Diastolic blood pressure (mmHg)	72.1	8.5	70.1	7.8	0.422†
Diabetic retinopathy					0.473*
n	9		13		
%	39.1		61.9		
Microalbuminuria					0.661*
n	2		2		
%	8.7		9.5		
Diabetes treatment (OA/I/OA + I/D) (%)	35/4/57/4		57/5/38/0		0.406*
ACE inhibitors					0.502*
n	16		13		
%	70		65		
Fasting plasma glucose (mmol/l)	7.4	2.7	7.9	2.2	0.524†
HbA1c (%)	6.8	0.9	6.9	0.6	0.740†
Total cholesterol (mmol/l)	5.2	0.9	5.6	1.3	0.234†
HDL-cholesterol (mmol/l)	1.3	0.3	1.3	0.2	0.832†
TAG (mmol/l)					0.972‡
Median	1.6		1.7		
Interquartile range	0.9–2.3		1.1–2.3		
LDL-cholesterol (mmol/l)	3.1	0.7	3.6	1.1	0.116†
UAE (mg/24 h)					0.981‡
Median	6.8		6.7		
Interquartile range	3.0–17.5		3.0–19.3		
Serum creatinine (μmol/l)	79.6	17.7	70.7	17.7	0.172†
GFR (ml/min per 1.73 m ²)	84.8	16.6	89.2	16.7	0.390†
hs-CRP (mg/l)					0.285‡
Median	2.8		1.9		
Interquartile range	1.1–5.3		0.8–5.2		
Endothelin-1 (pg/ml)	0.6	0.3	0.8	0.5	0.090†

GG, guar gum; OA, oral anti-diabetic agents; I, insulin; D, diet only; ACE, angiotensin-converting enzyme; HbA1c, glycated Hb; UAE, urinary albumin excretion; GFR, glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein.

* Pearson χ^2 .

† Student's *t* test.

‡ Mann–Whitney *U* test.

Table 2. Daily diet of patients with type 2 diabetes and the metabolic syndrome (Mean values and standard deviations; medians and interquartile ranges with the analysed features)

	Baseline		4 weeks		6 weeks		<i>P</i> *
	Mean	SD	Mean	SD	Mean	SD	
Energy (kJ)							
GG group	433.5	124.3	402.7†	109.2	406.3	104.9	0.029
Control group	421.9	136.1	365.2†	97.8	371.3‡	88.8	0.006
Protein (g)							
GG group	89.9	14.5	85.3	14.3	81.5	15.4	0.209
Control group	91.8	17.1	82.6†	14.8	86.3‡§	12.0	0.002
Carbohydrate (g)							
GG group	210.1	32.1	180.8†	23.8	184.2‡	28.1	<0.001
Control group	214.5	32.0	189.8†	26.0	191.9‡§	27.3	<0.001
Total fibre (g)							
GG group							
With PHGG¶	17.8	8.1	24.2†	5.1	24.3‡	5.4	<0.001
Without PHGG	17.8	8.1	14.2†	5.1	14.3‡	5.4	0.003
Control group	18.2	6.6	14.9†	6.2	15.7‡	6.3	0.035
Soluble fibre (g)							
GG group							
With PHGG¶	5.2	2.2	14.7†	1.8	14.8‡	1.9	<0.001
Without PHGG	5.2	2.2	4.7	1.8	4.8	1.9	0.177
Control group	5.7	1.9	5.0	1.9	5.2	1.9	0.216
Insoluble fibre (g)							
GG group	12.6	6.1	9.4†	3.5	9.5‡	3.6	0.001
Control group	12.6	4.8	9.9†	4.5	10.5	4.7	0.019
Total fat (g)							
GG group	66.3	11.6	60.9†	8.5	61.5‡	10.2	0.010
Control group	63.8	14.9	58.7	12.9	58.3‡	12.8	0.037
SFA (g)							
GG group	19.5	5.8	17.8	3.8	17.6‡	4.3	0.049
Control group	18.3	5.5	15.8†	3.4	16.1‡	3.5	0.036
MUFA (g)							
GG group	21.3	4.3	18.4†	2.7	19.0‡	3.8	0.007
Control group	21.3	6.8	17.8†	3.6	17.8‡	3.7	0.015
Trans-FA (g)							
GG group							0.058
Median	1.8		1.2		1.3		
Interquartile range	1.1–4.1		0.8–3.2		1.0–2.3		
Control group							0.001
Median	1.6		1.0†		1.1‡		
Interquartile range	1.2–2.6		0.8–1.3		0.8–1.5		

GG, guar gum; PHGG, partially hydrolysed guar gum; FA, fatty acid.

* *P* value refers to the general linear model for repeated measurements.

† Mean values were significantly different from those of baseline ($P < 0.05$; least significant difference (LSD) *post hoc* test).

‡ Mean values were significantly different from those of baseline ($P < 0.05$; LSD *post hoc* test).

§ Mean values were significantly different from those of 4 weeks ($P < 0.05$; LSD *post hoc* test).

|| Nutrient values adjusted for total energy daily intake.

¶ Baseline values before receiving PHGG.

Abnormal WC appears to be a constant feature in patients with the MetS⁽¹⁹⁾. A longitudinal survey has indicated that central obesity may precede the onset of other MetS components⁽³⁰⁾. Furthermore, central obesity is a risk factor for stroke, CHD and total mortality, independent of and additive to total obesity⁽³¹⁾. In a cohort of US men, a daily intake of 12 g of total fibre was associated with a 0.63 cm decrease in WC⁽³²⁾. In the present study, there was a 1.2 cm reduction in WC resulting from the intake of 10 g of supplementary PHGG, regardless of weight changes. This effect may be linked to the reduction of postprandial plasma insulin responses by fibre intake⁽³³⁾ and, consequently, appetite and energy intake⁽³⁴⁾. The increase in satiety from soluble fibres may result from other factors besides the insulin response: intrinsic physical properties of the fibre; modulation of gastric

motor function; possible influence on gut peptide hormones involved in signalling satiation, such as GLP-1^(5,35). Fibre intake may also affect the distribution of body fat, since the expression of the effects of insulin may be more marked in abdominal visceral than in subcutaneous adipocytes⁽³⁶⁾.

A glucose-lowering effect of high fibre intake in patients with diabetes has been described^(37,38). Our patients who received PHGG supplementation had a 0.3% reduction in HbA1c values. This reduction is relevant, since it occurred in patients using metformin and/or insulin, whose HbA1c values were already within the recommended glucose control target (<7.0%)⁽³⁹⁾. This effect would probably be even more pronounced in patients with a poor glycaemic control. Furthermore, this HbA1c reduction was achieved without weight gain or other major adverse effects that are often

Table 3. Metabolic syndrome components in patients with type 2 diabetes and the metabolic syndrome (Mean values and standard deviations; medians and interquartile ranges with the analysed feature)

	Baseline		4 weeks		6 weeks		P
	Mean	SD	Mean	SD	Mean	SD	
Waist circumference (cm)							
GG group	103.5	9.5	102.1*	10.0	102.3†	9.7	0.041‡
Control group	101.8	8.0	100.4	8.2	100.7	8.2	0.138‡
TAG (mmol/l)							
GG group							0.530§
Median	1.6		1.5		1.5		
Interquartile range	0.9–2.3		1.0–2.1		1.2–2.1		
Control group							0.750§
Median	1.7		1.5		1.5		
Interquartile range	1.1–2.3		1.1–1.9		0.9–2.2		
HDL-cholesterol (mmol/l)							
GG group	1.3	0.3	1.3	0.4	1.4	0.4	0.397§
Control group	1.3	0.3	1.3	0.3	1.3	0.3	0.593§
Systolic blood pressure (mmHg)							
GG group	128.4	16.2	129.1	11.9	132.4	10.2	0.127‡
Control group	130.1	11.6	126.4	13.1	128.0	13.7	0.800‡
Diastolic blood pressure (mmHg)							
GG group	72.1	8.5	71.1	8.3	72.4	9.9	0.774‡
Control group	70.1	7.8	65.4	7.4	67.0	5.7	0.287‡
Fasting plasma glucose (mmol/l)							
GG group	7.4	2.7	6.7	1.5	7.1	2.8	0.209
Control group	7.9	2.2	7.1	2.1	7.1	1.8	0.054

GG, guar gum.

* Mean value was significantly different from that of baseline ($P < 0.05$; least significant difference (LSD) *post hoc* test).

† Mean value was significantly different from that of 4 weeks ($P < 0.05$; LSD *post hoc* test).

‡ P value refers to the general linear model (GLM) for repeated measurements adjusted for changes in weight.

§ P value refers to the GLM for repeated measurements adjusted for changes in total fat intake.

associated with many anti-diabetic medications⁽⁴⁰⁾. The reduction in HbA1c (0.3%) is comparable with that accepted as significant in clinical trials when a novel drug is added to conventional anti-hyperglycaemic agents⁽⁴¹⁾.

Although PHGG has a lower viscosity and molecular weight than the intact GG, it has a similar biological action⁽⁴²⁾. It is known that soluble fibre, including PHGG, increases the viscosity of gut contents, reducing glucose diffusion through the unstirred water layer and the accessibility of α -amylase to its substrates, and decreases pancreatic enzyme activities^(5,42). These effects can blunt the postprandial increase in glucose and insulin, resulting in HbA1c decrease. This possibility is underscored by the demonstration that the relative contribution of postprandial glucose to HbA1c values is almost 70% when HbA1c is close to 7%⁽⁴³⁾. A recent study has also confirmed that this contribution of postprandial glucose is increased with low HbA1c values⁽⁴⁴⁾.

The observed reduction in UAE resulting from the PHGG fibre supplement, although transitory, is important, especially considering the low UAE values in this sample. Interestingly, albuminuria was once considered by the WHO as a MetS component⁽⁴⁵⁾. Indeed, high normal levels of albuminuria are predictive of macroalbuminuria and increased mortality in patients with type 2 diabetes⁽⁴⁶⁾. Supplementary soluble fibres have retarded the development of diabetic nephropathy in genetically diabetic mice⁽⁴⁷⁾, while GG has reduced UAE in streptozotocin-induced diabetic rats⁽⁴⁶⁾. In human subjects, the adoption of a high-fibre-content diet, rich in fruits and vegetables, has been reported to reduce UAE in pre-hypertensive

non-diabetic subjects⁽⁴⁸⁾. In fact, the effects of fibre intake on renal function are an almost unexplored issue. Given that UAE may reflect generalised vascular damage⁽⁴⁹⁾, anti-inflammatory properties of fibres⁽⁵⁰⁾ could partially explain its reduction. However, in the present study, there were no changes in the evaluated inflammatory markers.

The present data show that supplementation with PHGG was able to promote a reduction in serum *trans*-FA, even though the significance of this finding was borderline following the *post hoc* analysis. Nevertheless, we believe that this observation is in accordance with previous findings from the dietary reduction of *trans*-FA. Studies have shown that the reduction of *trans*-FA intake can be associated with reduced WC⁽³²⁾, cardiovascular risk⁽⁵¹⁾ and improved insulin sensitivity⁽⁵²⁾. The effects of serum *trans*-FA reduction by PHGG seem to be related to a common effect of soluble fibre: after ingestion, soluble fibres form gels that can reduce the intestinal absorption of nutrients. This effect occurs independent of the intake of this type of fat as observed in the present study. Since sources of serum *trans*-FA are only from the diet, their reduction by fibre intake may be more evident than that observed for other serum FA.

There was no reduction in total and LDL-cholesterol in the present study. This lack of fibre effect can be explained by baseline values very close to the normal reference range in all the studied patients. It should be noted, however, that the present results converge with a small borderline HDL-cholesterol-lowering effect of dietary fibre with no changes in TAG⁽⁵³⁾, as described previously.

Table 4. Selected cardiovascular risk factors evaluated in patients with type 2 diabetes and the metabolic syndrome

(Mean values and standard deviations; medians and interquartile ranges with the analysed feature)

	Baseline		4 weeks		6 weeks		P
	Mean	SD	Mean	SD	Mean	SD	
Weight (kg)							
GG group	79.6	14.8	79.0	15.2	79.2	15.1	0.199
Control group	77.0	13.5	76.2*	13.3	76.1†	13.4	0.005
HbA1c (%)							
GG group	6.9	0.9	6.6*	0.9	6.6†	0.8	0.040‡
Control group	7.0	0.6	6.9	1.0	6.9	0.9	0.392‡
UAE (mg/24 h)							
GG group							0.045§
Median	6.8		4.5*		6.2		
Interquartile range	3.0–17.5		3.0–10.5		3.0–9.5		
Control group							0.419§
Median	6.7		3.0		7.6		
Interquartile range	3.0–19.3		3.0–7.5		3.0–15.8		
Total cholesterol (mmol/l)							
GG group	5.2	0.9	5.3	0.7	5.5	1.1	0.188
Control group	5.6	1.3	5.4	1.2	5.4	1.1	0.633
LDL-cholesterol (mmol/l)							
GG group	3.1	0.7	3.2	0.5	3.3	0.8	0.589
Control group	3.6	1.1	3.4	1.0	3.4	0.9	0.409
GFR (ml/min per 1.73 m ²)							
GG group	84.8	16.6	82.0	19.4	85.0	16.2	0.355¶
Control group	89.2	16.7	88.5	18.9	89.0	17.4	0.739¶
hs-CRP (mg/l)							
GG group							0.252
Median	2.8		2.5		2.1		
Interquartile range	1.1–5.2		0.8–4.2		0.8–7.9		
Control group							0.875
Median	1.9		1.9		1.5		
Interquartile range	0.8–5.2		0.5–4.5		0.7–4.0		
Endothelin-1 (pg/ml)							
GG group	0.6	0.3	0.7	0.4	0.6	0.3	0.267
Control group	0.8	0.5	0.7	0.4	0.7	0.4	0.891

GG, guar gum; HbA1c, glycated Hb; UAE, urinary albumin excretion; GFR, glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein.

* Mean values were significantly different from those of baseline ($P < 0.05$; least significant difference (LSD) *post hoc* test).† Mean values were significantly different from those of 4 weeks ($P < 0.05$; LSD *post hoc* test).

‡ P value refers to the general linear model (GLM) for repeated measurements adjusted for weight changes and HbA1c at baseline.

§ P value refers to the GLM for repeated measurements adjusted for changes in weight, systolic and diastolic blood pressure, protein intake and HbA1c

|| P value refers to the GLM for repeated measurements adjusted for total fat intake changes.

¶ P value refers to the GLM for repeated measurements adjusted for changes in systolic and diastolic blood pressure, protein intake and HbA1c.

Possible limitations of the present study are related to unintentional changes in dietary components other than fibre. Probably these changes were not related to the information obtained from dietary diaries, given that the adopted 3 d weighed dietary record method was standardised previously⁽²³⁾ and includes dietary information from 2 d of the week and one weekend day. The observed reduction in dietary intake could be partially explained by more frequent visits and surveillance, since patients were frequently monitored by the dietitian and the physician. Accordingly, dietary modifications occurred both in the GG and control groups and did not differ between them. These unintentional changes were included as covariates in the multivariate analysis to control this potential interference. Furthermore, the unintentional weight loss observed only in the control group, possibly explained by a sustained reduction in energy intake up to

the 6th week, could represent another limitation. Then, we also included weight changes as a covariate in the analyses of HbA1c, WC and blood pressure changes, and the results did not change. Another restriction that could preclude the generalisation of the present data is associated with the good glycaemic, lipid and blood pressure control already present at baseline in our patients. Nevertheless, the effect of soluble fibre supplementation might be assumed to be even more beneficial in diabetic patients with a poor glucose control. The lack of a placebo group in the present study could also represent a limitation. However, it is difficult to find a proper placebo that matches the physical characteristics of PHGG (tasteless white powder). For example, using an insoluble fibre as the placebo probably would not represent an actual placebo since insoluble fibres could also have some metabolic effects⁽⁵⁾. Moreover, we have to consider

that patients receiving PHGG may have gastrointestinal symptoms that easily would identify the active treatment. In fact, we observed that seventeen from twenty-three patients in the GG group reported gastrointestinal complaints.

The results of the present study suggest that patients with diabetes should have a dose of 10 g PHGG added to their usual diet to improve their MetS profile. From a practical, clinical perspective, patients can be encouraged to include a fibre-rich food, especially soluble fibre, in their diet. For example, the intake of 10 g of soluble fibre would mean a daily consumption of two tablespoons of oats (30 g), two slices of rye bread (50 g), a ladle of black beans (140 g), a slice of papaya (150 g) and an orange (180 g). However, additional investigation will be necessary to confirm whether soluble fibres from foods have similar metabolic effects when compared with PHGG. This beneficial effect should be confirmed in randomised clinical trials using natural food sources of soluble fibres.

Conclusions

In conclusion, in patients with type 2 diabetes and the MetS, the addition of PHGG to the usual diet improved the MetS profile and factors associated with cardiovascular risk by reducing WC, HbA1c, UAE and *trans*-FA. This soluble fibre consumption might be included in the dietary management of type 2 diabetic patients.

Acknowledgements

The present study was supported by grants from Projeto de Núcleos de Excelência do Ministério de Ciência e Tecnologia, Ministério de Ciência e Tecnologia, Conselho Nacional de Desenvolvimento Científico e Tecnológico and FIPE – Hospital de Clínicas de Porto Alegre. V. D. was the recipient of scholarships from CNPq and F. M. S. from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. T. S. received a grant from Projeto Nacional de Pós-Doutorado (PNPD 03021/09-2). Bread was provided by Nutrella, soyabean oil by Bunge and Benefiber® by Novartis Brasil. We thank Dr Magda Perassolo for helping with the endothelin-1 measurements. The authors' contributions were as follows: V. D., M. J. A. and J. L. G. designed the research; V. D., M. J. A., F. M. S., C. P. R. and J. P. A. conducted the research; V. D. and M. J. A. performed the statistical analyses and wrote the paper; V. D., M. J. A. and J. L. G. had primary responsibility for the final content; V. D., F. M. S., J. P. A., T. S. and J. C. A. performed the FA measurements. None of the authors had a personal or financial conflict of interest.

References

1. Alberti KG, Eckel RH, Grundy SM, *et al.* (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* **120**, 1640–1645.
2. Mottillo S, Filion KB, Genest J, *et al.* (2010) The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. *J Am Coll Cardiol* **56**, 1113–1132.
3. Ley SH, Harris SB, Mamakeesick M, *et al.* (2009) Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community. *CMAJ* **180**, 617–624.
4. Costa LA, Canani LH, Lisboa HR, *et al.* (2004) Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. *Diabet Med* **21**, 252–255.
5. Papathanasopoulos A & Camilleri M (2009) Dietary fiber supplements: effects in obesity and metabolic syndrome and relationship to gastrointestinal functions. *Gastroenterology* **138**, 65–72.
6. Esposito K, Marfella R, Ciotola M, *et al.* (2004) Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. *JAMA* **292**, 1440–1446.
7. Azadbakht L, Mirmiran P, Esmailzadeh A, *et al.* (2005) Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. *Diabetes Care* **28**, 2823–2831.
8. Silva FM, Steemburgo T, de Mello V, *et al.* (2011) High dietary glycemic index and low fiber content are associated with metabolic syndrome in patients with type 2 diabetes. *J Am Coll Nutr* **30**, 141–148.
9. Steemburgo T, Dall'Alba V, Almeida JC, *et al.* (2009) Intake of soluble fibers has a protective role for the presence of metabolic syndrome in patients with type 2 diabetes. *Eur J Clin Nutr* **63**, 127–133.
10. Yoon SJ, Chu DC & Raj Juneja L (2008) Chemical and physical properties, safety and application of partially hydrolyzed guar gum as dietary fiber. *J Clin Biochem Nutr* **42**, 1–7.
11. Slavin JL & Greenberg N (2003) Partially hydrolyzed guar gum: clinical nutrition uses. *Nutrition* **19**, 549–552.
12. Calvo-Rubio Burgos M, Montero Pérez FJ, Campos Sánchez L, *et al.* (1989) Use of guar gum as a supplement to the usual diet in type 2 diabetes. A long-term study. *Aten Primaria* **6**, 20–30.
13. Chuang LM, Jou TS, Yang WS, *et al.* (1992) Therapeutic effect of guar gum in patients with non-insulin-dependent diabetes mellitus. *J Formos Med Assoc* **91**, 15–19.
14. Aro A, Uusitupa M, Voutilainen E, *et al.* (1981) Improved diabetic control and hypocholesterolaemic effect induced by long-term dietary supplementation with guar gum in type 2 (insulin-independent) diabetes. *Diabetologia* **21**, 29–33.
15. Lalor BC, Bhatnagar D, Winocour PH, *et al.* (1990) Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. *Diabet Med* **7**, 242–245.
16. Niemi MK, Keinänen-Kiukaanniemi SM & Salmela PI (1988) Long-term effects of guar gum and microcrystalline cellulose on glycaemic control and serum lipids in type 2 diabetes. *Eur J Clin Pharmacol* **34**, 427–429.
17. Uusitupa M, Siitonen O, Savolainen K, *et al.* (1989) Metabolic and nutritional effects of long-term use of guar gum in the treatment of noninsulin-dependent diabetes of poor metabolic control. *Am J Clin Nutr* **49**, 345–351.
18. Stahl M & Berger W (1990) Compared effect of guar gum, wheat bran and placebo on carbohydrate and lipid metabolism in type II diabetic. *Schweiz Med Wochenschr* **120**, 402–408.

19. Alberti KG, Zimmet P & Shaw J (2006) Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* **23**, 469–480.
20. Chobanian AV, Bakris GL, Black HR, *et al.* (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* **42**, 1206–1252.
21. Gross JL, Azevedo MJ, Silveiro SP, *et al.* (2005) Diabetic nephropathy: diagnosis, prevention, and treatment. *Diabetes Care* **28**, 164–176.
22. Tuomilehto J, Lindström J, Eriksson JG, *et al.* (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* **344**, 1343–1350.
23. Moulin CC, Tiskievicz F, Zelmanovitz T, *et al.* (1998) Use of weighed diet records in the evaluation of diets with different protein contents in patients with type 2 diabetes. *Am J Clin Nutr* **67**, 853–857.
24. USDA SR 13 (1998) *Research Quality Nutrient Data: The Agricultural Research Service: Composition of Foods. Agricultural Handbook*, no. 8. Washington, DC: US Department of Agriculture.
25. Schakel S, Sievert YA, Buzzard IM (2001) Dietary fiber values for common foods. In *CRC Handbook of Dietary Fiber in Human Nutrition*, 3rd ed., pp. 615–648 [GA Spiller, editor]. Boca Raton, FL: CRC Press.
26. Almeida JC, Zelmanovitz T, Vaz JS, *et al.* (2008) Sources of protein and polyunsaturated fatty acids of the diet and microalbuminuria in type 2 diabetes mellitus. *J Am Coll Nutr* **27**, 528–537.
27. Levey AS, Stevens LA, Schmid CH, *et al.* (2009) A new equation to estimate glomerular filtration rate. *Ann Intern Med* **150**, 604–612.
28. Perassolo MS, Almeida JC, Pra RL, *et al.* (2003) Fatty acid composition of serum lipid fractions in type 2 diabetic patients with microalbuminuria. *Diabetes Care* **26**, 613–618.
29. Willett W & Stampfer MJ (1986) Total energy intake: implications for epidemiologic analyses. *Am J Epidemiol* **124**, 17–27.
30. Cameron AJ, Boyko EJ, Sicree RA, *et al.* (2008) Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. *Obesity (Silver Spring)* **16**, 2707–2716.
31. Klein S, Allison DB, Heymsfield SB, *et al.* (2007) Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. *Am J Clin Nutr* **85**, 1197–1202.
32. Koh-Banerjee P, Chu NF, Spiegelman D, *et al.* (2003) Prospective study of the association of changes in dietary intake, physical activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16 587 US men. *Am J Clin Nutr* **78**, 719–727.
33. Pereira MA & Ludwig DS (2001) Dietary fiber and body-weight regulation. *Pediatr Clin North Am* **48**, 1–9.
34. Roberts SB (2000) High-glycemic index foods, hunger and obesity: is there a connection? *Nutr Rev* **58**, 163–170.
35. Heini AF, Lara-Castro C, Schneider H, *et al.* (1998) Effect of hydrolyzed guar fiber on fasting and postprandial satiety and satiety hormones: a double-blind, placebo-controlled trial during controlled weight loss. *Int J Obes Relat Metab Disord* **22**, 906–909.
36. Bjorntorp P (1996) The regulation of adipose tissue distribution in humans. *Int J Obes Relat Metab Disord* **20**, 291–302.
37. Anderson JW, Randles KM, Kendall CW, *et al.* (2004) Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence. *J Am Coll Nutr* **23**, 5–17.
38. Post RE, Mainous AG 3rd, King DE, *et al.* (2012) Dietary fiber for the treatment of type 2 diabetes mellitus: a meta-analysis. *J Am Board Fam Med* **25**, 16–23.
39. American Diabetes Association (2012) Standards of medical care in diabetes – 2012. *Diabetes Care* **35**, Suppl. 1, S11–S63.
40. Gross JL, Kramer CK, Leitão CB, *et al.* (2011) Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. *Ann Intern Med* **154**, 672–679.
41. US Food and Drug Administration (2008) Guidance for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. <http://www.fda.gov/cder/guidance/7630dft.pdf> (accessed 28 May 2010).
42. Yoon SJ, Chu DC & Raj Juneja L (2006) Physiological functions of partially hydrolyzed guar gum. *J Clin Biochem Nutr* **39**, 134–144.
43. Monnier L, Lapinski H & Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). *Diabetes Care* **26**, 881–885.
44. Riddle M, Umpierrez G, DiGenio A, *et al.* (2011) Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. *Diabetes Care* **34**, 2508–2514.
45. Alberti KG & Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* **15**, 539–553.
46. Murussi M, Campagnolo N, Beck MO, *et al.* (2007) High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian type 2 diabetic patients: an 8-year follow-up study. *Diabet Med* **24**, 1136–1142.
47. Lee SM (1982) The effect of a high fibre diet on diabetic nephropathy in the db/db mouse. *Diabetologia* **22**, 349–353.
48. Gallaher DD, Olson JM & Larntz K (1992) Dietary guar gum halts further renal enlargement in rats with established diabetes. *J Nutr* **122**, 2391–2397.
49. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, *et al.* (1989) Albuminuria reflects widespread vascular damage. The Steno hypothesis. *Diabetologia* **32**, 219–226.
50. Jacobs DR Jr, Gross MD, Steffen L, *et al.* (2009) The effects of dietary patterns on urinary albumin excretion: results of the Dietary Approaches to Stop Hypertension (DASH) Trial. *Am J Kidney Dis* **53**, 638–646.
51. Mozaffarian D, Katan MB, Ascherio A, *et al.* (2006) *Trans* fatty acids and cardiovascular disease. *N Eng J Med* **354**, 1601–1613.
52. Hu FB, van Dam RM & Liu S (2001) Diet and risk of type II diabetes: the role of types of fat and carbohydrate. *Diabetologia* **44**, 805–817.
53. Brown L, Rosner B, Willett WW, *et al.* (1999) Cholesterol-lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr* **69**, 30–42.